Introduction O besity is the major contributing cause of type 2 diabetes, coronary artery disease, stroke, gallbladder disease, musculoskeletal disorders, and certain cancers, as well as all-cause mortality. [1] [2] [3] Obesity is consistently associated with increased health care utilization (HCU) such as primary and specialized care, and hospitalizations, imposing large and increasing health care-related costs (HCC) on society. [4] [5] [6] Bertakis et al. showed that obesity (BMI ! 30) and severe obesity (BMI > 40) have been associated with a 50% and 100% increase in per capita health care costs, respectively. 4, 5 MD and anxiety are also major public health problems and are associated with a number of physical conditions, such as cardiovascular diseases, type 2 diabetes and cancer, among others. 3, 7 Vogelzangs et al. showed that persons with current major depression (MD) or anxiety disorders were 1.37, 3.54, 4.96 and 4.75 times more likely to have stroke, coronary heart disease, angina pectoris and myocardial infarction compared to those without MD/anxiety, respectively. 7 It has also been estimated that one in three adult primary care patients has a full or subclinical depressive disorder. 8 Evidence is growing that obesity and MD/anxiety often co-occur and are inter-related. [9] [10] [11] [12] [13] The potential vicious cycle between these two conditions is assumed to be centered around inflammation, 14 since both obese and depressed persons exhibit increased inflammatory markers, such as C -reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha. [14] [15] [16] [17] [18] These inflammatory markers are found to be associated with an increased risk of chronic diseases.
14 Obesity and MD/anxiety also share pleiotropic genes, and it seems that they might have a common etiology, which makes them valuable to examine. 11, 13, 18 This suggests that obesity and MD/anxiety exacerbate each other through a common pathway, i.e. inflammation or genetic susceptibility thereby increases chronic disease morbidity. Thus, we expect that persons with both obesity and MD/anxiety have markedly increased HCU and HCC compared to persons with either of the condition alone. This leads to a hypothesis that the joint association of obesity and MD/anxiety is stronger than the sum of their separate associations regarding HCU and HCC. Therefore, the main objective of the present study is to examine the separate and joint longitudinal associations of obesity and MD/anxiety with risks of increased HCU and HCC over time.
Methods

Study design and population
Data were derived from an ongoing longitudinal cohort study, the Netherlands Study of Depression and Anxiety (NESDA). NESDA examines the etiology, course, and consequences of depressive and anxiety disorders. 19 A total of N = 2,981 persons were included, aged 18 through 65 years recruited from the community, general practice and secondary care. Exclusion criteria were 1) a primary clinical diagnosis of another psychiatric disorder (i.e. psychotic disorder, obsessive-compulsive disorder, bipolar disorder, or severe addiction disorder), and 2) not being fluent in Dutch. From the original cohort of N = 2981 subjects, we included N = 2706 persons with complete data on the variables of interest at baseline.
After baseline measurement (2004) (2005) (2006) (2007) , extensive face-to-face and questionnaire-based assessments at 2-year (2006-2009), 4-year (2008-2013) and 6-year (2010-2013) follow-up were conducted. The loss to follow-up was defined as no follow-up after baseline assessment, which was 19%, and was associated with lower educational status and the occurrence of depressive/anxiety disorders, but not with age, gender, household income and obesity.
The NESDA study protocol was approved by the Ethical Review Board of the VU University Medical Center and subsequently by local review boards of each participating center. The study was conducted in accordance with the Declaration of Helsinki.
Measurements
General and abdominal obesity
We assessed general obesity with the body mass index (BMI), calculated from body weight (kg) and height (m) measured at each wave. Body weight and height were measured by well-trained research staff. Participants were classified into two BMI categories according to the standard international classification of the World Health Organization (WHO): non-obese < 30 kg/m 2 , and obese ! 30.0 kg/m 2 .
Abdominal obesity was defined as having a waist circumference (WC) of !102 cm for males and !88 cm for females.
20,21
Major depression and anxiety disorders Major depression and anxiety disorders (generalized anxiety disorder, social phobia, panic disorder and agoraphobia) were assessed using the Composite International Diagnostic Interview (CIDI), version 2.1, at each wave. The CIDI is a highly reliable and valid lay-administered structured interview and diagnoses according to the definitions and criteria of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 22 The interview was conducted by CIDI-trained interviewers (e.g. graduate students in psychology) under the supervision of clinicians. As remitted MD/anxiety disorders is not associated with obesity, 23 current MD/anxiety disorders was dichotomized into individuals who were diagnosed positive and negative for the DSM-IV criteria of MD/anxiety disorders in the past 6 months. 24 
Health care utilization
Health care utilization (HCU) concerned outpatient visits to primary and specialty care, and hospitalizations at each wave. This included accident and emergency care with these physicians, but we had no data on the degree to which this was the case. This information was assessed by the Trimbos/iMTA questionnaire on healthcare consumption and illness (Tic-P). 25 Health care-related costs (HCC) for outpatient visits were calculated by multiplying the number of General practitioner (GP) contacts/visits by E29, and of specialty care visits by E75 based on the Dutch manual for costing. 26 The recall period of the questions was 6 months, and the annualized costs were calculated by multiplying the estimated costs by two. All costs are expressed in Euro (E). As the number of participants admitted to a hospital > 1 was very few during 6 months, we did not calculate the hospitalization costs. We assumed that primary and specialty care-related costs can be used as a proxy for hospitalization costs.
Statistical analyses
Data were analysed in four steps. First, we described the baseline sample characteristics by obesity and/or MD/anxiety disorder status. Second, we examined the separate longitudinal associations of general obesity t x , abdominal obesity t x , and MD/anxiety disorders t x with HCU t x+1 using GEE (Generalized Estimating Equations) binary logistic regression, 27, 28 with t x being a given wave and t x+1 being the next wave. GEE allows observations to be correlated over time and to have missing values at varying measurement points. 27 All analyses were adjusted for age and gender. We also adjusted for any potential relationship between age and the determinants and outcome by including age and age-squared in the models. We checked interactions between obesity and/or MD/anxiety disorders Â gender and obesity and/or MD/anxiety disorders Â time by entering the interaction terms in the gender or time-adjusted models for the outcome variable.
Third, we examined whether the joint association of obesity t x and MD/anxiety disorders t x with HCU t x+1 is stronger than the sum of separate associations of obesity and MD/anxiety disorders with HCU. We created a 4-category variable, non-obese and nondepressed, obese, depressed/anxiety, and both obese and depressed/anxiety. If obesity was present, then i = 1 otherwise i = 0. If MD/anxiety disorders was present, then j = 1 otherwise j = 0. Then, OR ij represented the OR in both obese and depressed/anxiety disorders category i, j. The three OR estimates [(i.e. OR 11 , OR 10 , OR 01 ), and OR 00 (reference category)] were computed from GEE analyses. The relative excess risk due to interaction (RERI) was used to assess the additional risk due to joint exposures of obesity and MD/anxiety disorders compared with the sum of the separate risks for obesity and MD/anxiety disorders regarding higher HCU. RERI was defined as: RERI = OR 11 -OR 10 -OR 01 +1. 29 A positive interaction of obesity and MD/anxiety disorders with HCU is reflected by a RERI >0, while a RERI < 0, represents a negative interaction of obesity and MD/anxiety; RERI = 0 indicates that there is no interaction (additivity) in the association of obesity and MD/anxiety disorders with HCU. Confidence intervals (CIs) for the RERI were calculated using covariances of parameter estimates from GEE models. 29 Fourth, we examined the separate and joint associations of obesity t x and MD/anxiety disorders t x with HCC 2 years later during a 6-year follow-up using GEE-time lag models. Given the skewed nature of the HCC for primary and specialty care variables, we used GEE with a log-link function and a gamma distribution. 30 GEE gamma regression model results should therefore be interpreted in terms of proportional or multiplicative differences. 31 For instance, in table 3, 188/148 = 1.27, indicates that obese persons have 1.27 times higher increase in primary care HCC compared to their non-obese counterparts, which is equivalent to 27% increase in HCC for obese persons.
All statistical analyses were performed using SPSS version 22.0. Effects were considered significant when P < 0.05.
Results
Characteristics of the sample Table 1 shows the baseline characteristics of N = 2706 subjects by obesity and/or MD/anxiety disorders status. At baseline, the prevalences of general obesity and abdominal obesity, and MD/anxiety disorders were 16, 35 and 57%, respectively. The median (interquartile range, IQR) number of primary and speciality care visits during 6 months were 2 (1-3) and 0 (0-1), respectively. The annual HCC (E) associated with primary and speciality care by obesity and/or MD/anxiety disorders status are depicted in We also found a longitudinal association between MD/anxiety disorders at t x and primary care visits at t x+1 OR = 1.35 (1.20; 1.52). Adjustment for age and gender slightly attenuated the association, but remained statistically significant. However, MD/anxiety disorders at t x was not associated with specialty care visits and hospitalizations at t x+1 (table 2) .
Joint associations of obesity and MD/anxiety disorders with HCU
Longitudinal associations were found between obesity and MD/ anxiety disorders at t x and primary-and specialty care visits, and hospitalizations at t x+1 with OR (95%-CI)=1.83 (1.44; 2.34), 1.31(1.06; 1.61 and 1.79 (1.40; 2.29), compared to non-obese and non-depressed/anxious persons, respectively, (table 2) after adjustment of age and gender. The relative excess risks due to interaction (RERI (95%-CI)) between obesity and MD/anxiety disorders on primary care visits, specialty care visits, and hospitalizations were: 0.15 (À0.38, 0.68), 0.10 (À0.24, 0.43), and 0.00 (À0.53, 0.53), respectively (figure 1). Figure 1 shows the cumulative risk of health care use associated with the separate and joint exposures of obesity and MD/anxiety. We found similar results for the combinations of abdominal obesity and MD/anxiety disorders at t x with an increased risk of primary and specialty care visits and hospitalizations at t x+1 , with OR = 1. 62 (1.35; 1.95), 1.22 (1.04; 1.43 and 1.88 (1.54; 2.29), compared to non-obese and non-depressed/anxious persons, respectively (table 2) .
The separate and joint associations of obesity and MD/ anxiety disorders with HCC Table 3 shows the predicted 2-year subsequent HCC for primary and specialty care by obesity and/or MD/anxiety disorders status during 6-year follow-up. Obese persons had 27% and 25% higher increase in primary and specialty care costs 2 years later compared to their non-obese counterparts, respectively (table 3) . Persons with MD/ anxiety disorders had 24% higher increase in primary care costs compared to those without MD/anxiety disorders (table 3) , but not associated with an increase in specialty care costs. Table 2 The longitudinal separate and joint associations of obesity t x , major depression/anxiety t x , and their combination with health care use 2 years later t x+1 , using 6-year follow-up data Obesity along with MD/anxiety disorders at t x was longitudinally associated with an increase in primary and specialty care costs at t x + 1, mean cost ratio (95%-CI) =1.56 (1.27, 1.91) and 1.36 (1.15, 1.61) compared to non-obese and non-depressed/anxiety, respectively (table 3) , but the relative excess risks due to interactions between obesity and MD/anxiety disorders regarding HCU and HCC were not statistically significant (i.e. no synergistic effect), with a RERI = 0.17 (À0.16; 0.51) and À0.11 (À0.46, 0.23), respectively.
Discussion
In this 6-year longitudinal study, we examined the associations of obesity, MD/anxiety disorders and their combination with risks of increased HCU and HCC during the subsequent 2 years. Obesity was associated with an increased risk of all types of care except visits due to mental problems. MD/anxiety disorders were associated with an increased risk of primary care visits, but not specialty care visits and hospitalizations. The joint association of obesity and MD/anxiety disorders with higher HCU and HCC was slightly larger than would have been expected on the additive scale, but this increase was not statistically significant.
We found that obesity along with MD/anxiety disorders were significantly associated with an increased use of all types of care, and was slightly larger than would have been expected on the additive scale. For joint exposures of obesity and MD/anxiety, the additional risk of a primary care visit was 92%, while the risk attributable to obesity and MD/anxiety disorders was 78% (43% to obesity and 35% to MD/anxiety), leading to a RERI = 0.15 ( figure 1a) . Similarly, the RERI for specialty care visit was 0.10 ( figure 1b) . However, the additional risks were not statistically different (i.e. no synergistic effect). An explanation why the RERIs are not statistically significant may be that the interaction between obesity and MD/anxiety disorders needs more time to lead to more than additive effects. This may be due to having the benign phenotype of obesity, i.e. metabolically healthy obesity (MHO) because these phenotypes are transitional states prone to changes in their metabolic status, and have increased risks for adverse health outcomes when follow-ups longer than 10 years are considered. 32 Another explanation is that there is also a tendency that patients with MD/anxiety disorders show clinical recovery over time even though residual symptoms of depression or anxiety disorders often persist. 33, 34 Another, more pragmatic explanation why the RERI is not significant is the rather small sample size for the subgroup analysis of obesity and major depression status categories with HCU.
Another important finding is that persons with obesity alone and depression/anxiety disorders alone differ in HCU and HCC. Obesity alone (BMI ! 30) was longitudinally associated with an increased risk of primary and specialty care visits, and hospitalizations, which is in line with earlier studies. [4] [5] [6] [35] [36] [37] This is explained by the fact that obesity is related causally to serious medical illnesses, in which excess body weight increases the risk of the development of several chronic conditions. However, obesity was not associated with primary care visits due to mental problems during follow-up. This gives an insight that the physiological effects of obesity are more likely to increase HCU and HCC compared with its psychological effect (i.e. psychological complaints).
We found that persons with MD/anxiety disorders alone had a higher risk of primary care visits and costs, but not specialty care visits and hospitalizations. In line with our finding, Luppa et al. showed that depressed persons have an increased use of care and HCC compared to those who were not depressed. 38 In fact, the use of health care among depressed persons can be partly explained by age (e.g. older age) and the severity of depression (e.g. suicidal thoughts), decreased quality of life and higher co-morbidity of medical conditions. 8, 38 As presented in this study, the risks of increased use of specialty and inpatient care were significantly higher in persons with MD/anxiety disorders and obesity compared to those with MD/anxiety disorders alone. A possible explanation is that obesity is a state of chronic low-grade inflammation, which may exacerbate the psychological and/or physiological effects of depression thereby increasing HCU. 15, 16, 39 Another explanation may be that the greater frequency of specialty care visits among obese adults, and the direct consequence of both obesity and MD/ anxiety disorders on the development of chronic conditions such as type II diabetes, coronary heart disease, cerebrovascular disease, certain types of cancer.
1,3 Overall, we observed that the joint Table 3 The longitudinal associations of obesity t x , major depression/anxiety t x , and their combination with primary and specialty care costs (E) t x+1 two years later, using 6-year follow-up data Note. a: mean cost ratios between exposed and non-exposed groups with 95% confidence intervals; MD; major depression. b: Adjusted for age and gender, c: Waist circumference (WC) ! 102 cm for male and 88 cm for female.
exposures of obesity and MD/anxiety disorders lead to higher HCU and HCC compared with either of the conditions alone.
Strengths and limitations
The major strength of our study is its prospective design. We were able to examine longitudinal associations of obesity and MD/anxiety disorders at one point in time with HCU and HCC 2 years later over a 6-year follow-up period by using time-lag models (i.e. the temporal association was maintained). This supports assumptions on causality, though not conclusive ones. Moreover, we used CIDI interview to diagnose MD/anxiety disorders instead of self-reports as often used before. We assessed obesity using two anthropometric measurements i.e. BMI and WC, as many researchers have been criticizing the BMI for its inadequate reflection of body composition, which does not differentiate between fat mass and lean body mass, or between abdominal adiposity and general fatness.
We have to keep some limitations in mind. First, the NESDA study is a representative sample of a population with common mental disorders. Because of this, a rather large proportion of the participants had prevalent depressive or anxiety disorders, implying that non-depressed obese subjects may be underrepresented. Nevertheless, we expect that the study cohort is representative, and findings are generalizable to other settings in high-income countries because the prevalence of obesity in our study (16%) is comparable with that in the Dutch population, and within the range of the WHO European region prevalence (10-30%). Another limitation with respect to the outcome might be that the health care use information including medical visits, was based upon selfreport, which may have resulted in some information bias, e.g. by depressive respondents reporting higher use, and may have added some measurement error, i.e. underestimation regarding the interaction of depression and obesity. The estimated costs appeared smaller because we included major categories of health care services such as primary and specialty care costs. The estimation of costs over 12 months was derived from the recall period of 6 months, which may have resulted in measurement error in the HCC, but previous research has shown this issue to be nonsystematic i.e. not adding bias. 40 Implications for policy, practice and future research Obesity and MD/anxiety are major burdens for the patient, physicians and society. We showed that obesity and MD/anxiety are separately and jointly associated with an increased risk of HCU and HCC. If the RERIs of 0.15 and 0.10 for primary and specialty care are confirmed in future studies, the joint associations may have implications for policy and practice. Intervening on obesity may be more beneficial in individuals with MD/anxiety compared to those without MD/anxiety regarding the risks of primary and specialty care visits, and HCC. Moreover, individuals with MD/anxiety utilize more primary care resources than other categories of health care (i.e. specialty care and inpatient care). Therefore, careful consideration and may be monitoring of depressive symptoms and a more restraint use of antidepressants with the greatest weight stimulating effects may be recommended in primary care. Future studies should focus on whether it is possible to manage obesity and MD/anxiety synergistically regarding morbidity as well as excess use of care and costs.
In conclusion, our study suggests that obesity and MD/anxiety disorders impose a significant burden for HCU and HCC. The HCC of obesity and MD/anxiety disorders, derived from health care visits, are spread across a range of outpatient health services. However, the HCC associated with the joint presence of both conditions are not higher than the sum of the HCC due to each condition independently.
